Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG. Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. New England Journal Of Medicine 2004, 350: 1516-1525. PMID: 15071126, DOI: 10.1056/nejmoa031633.Peer-Reviewed Original ResearchConceptsParathyroid hormone levelsPrimary end pointSecondary hyperparathyroidismHormone levelsPlacebo groupCinacalcet groupLow parathyroid hormone levelsSerum calcium-phosphorus productIntact parathyroid hormone levelsEnd pointCalcium-phosphorus productEfficacy assessment phaseParathyroid hormone valuesPatients Receiving HemodialysisPlacebo-controlled trialPercentage of patientsAdverse clinical outcomesCalcium-phosphorus homeostasisCalcium-sensing receptorClinical outcomesVitamin DDaily dosesStandard treatmentHormone valuesCardiovascular disease